Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tenofovir disoproxil fumarate - Gilead Sciences

Drug Profile

Tenofovir disoproxil fumarate - Gilead Sciences

Alternative Names: Bis-POC-PMPA; GSK548470; PMPA-prodrug; Tenofovir DF; Tenozet; Viread

Latest Information Update: 10 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institute of Organic Chemistry and Biochemistry (Prague); Rega Institute for Medical Research
  • Developer Gilead Sciences; GlaxoSmithKline
  • Class Antiretrovirals; Phosphonic acids; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B; HIV infections

Most Recent Events

  • 10 Dec 2018 Adverse events and efficacy data from a phase III trial in Hepatitis B presented at the 69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2018)
  • 05 Dec 2018 Gilead offered Japan Tobacco to terminate the exclusive licenses for HIV drugs in Japan
  • 28 Aug 2018 Japan Tobacco and Gilead sign a letter of intent to initiate discussion to terminate license agreement for HIV drugs in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top